The performance of different in vitro diagnostic tests for the diagnosis of invasive aspergillosis (IA) was investigated in a transiently neutropenic rat model. Rats were immunosuppressed with cyclophosphamide and then inoculated intravenously with 1.5 ؋ 10 4 CFU Aspergillus fumigatus spores. Animals were then either treated with caspofungin acetate, 1 mg/kg/day for 7 days, or not treated. PCR-enzyme-linked immunosorbent assay (ELISA), real-time PCR, and galactomannan (GM) detection were performed on postmortem blood samples, along with culture of liver, lung, and kidney homogenate. Caspofungin-treated animals showed a decrease in residual tissue burden of A. fumigatus from organ homogenate compared to untreated animals (P < 0.002). PCR-ELISA returned positive results for 11/17 animals treated with antifungal agents and for 10/17 untreated animals. Galactomannan was positive in 8/17 caspofungin-treated animals and 4/17 untreated animals. Real-time PCR was positive in 2/17 treated and 3/17 untreated animals. This study demonstrates that PCR-ELISA is a more sensitive test than either GM detection (P ‫؍‬ 0.052) or real-time PCR (P < 0.01) for diagnosis of IA but that any of the three tests may return false-negative results in cases of histologically proven disease. Galactomannan indices from animals treated with antifungal agents showed a trend (P ‫؍‬ 0.1) towards higher levels than those of untreated animals, but no effect was observed with PCR-ELISA indices (P ‫؍‬ 0.29). GM detection, as previously described, may be enhanced by the administration of caspofungin, but PCR-ELISA appears not to be affected in the same way. We conclude that PCR-ELISA is a more sensitive and reliable method for laboratory diagnosis of IA.
Invasive aspergillosis (IA) is a leading cause of death in neutropenic bone marrow transplant patients, patients receiving cytotoxic chemotherapy for leukemia, and solid organ transplant patients (3, 17, 22) . The incidence has been estimated to be 5 to 25% in patients with acute leukemia, with mortality approaching 100% (8, 10, 18, 29) .
Early and accurate diagnosis of IA is a worthy goal, as it has the potential to improve outcomes by targeting antifungal therapy more effectively. A number of laboratory strategies to improve the early diagnosis of IA have been published, including PCR amplification of Aspergillus DNA sequences from blood and other body fluids (6, 9, 14, 16, 28, 32, 36, 40) and detection of cell wall components such as galactomannan (GM) (13, 21, 34, 35, 37) .
While studies have generally reported very promising results for new, non-culture-based strategies to diagnose IA in the laboratory, problems surrounding clinical validation of the assays has delayed the inclusion of these strategies in routine clinical and laboratory use. A number of parameters remain to be investigated, including the kinetics of fungal cell elements in the blood and the effect that administration of systemic antifungal agents may have on the detection of these elements. As a result, uncertainty surrounding the optimal use of these diagnostic strategies remains.
The aim of the present study was to study the effect of the administration of caspofungin acetate on the performance of GM and PCR testing and to determine if the phenomenon of intermittent positive results in a subject with heavy fungal burden is a true phenomenon or a function of concomitant antifungal treatment.
To this end, we heavily infected transiently neutropenic rats with Aspergillus spores, treated one group with 1 mg/kg/day caspofungin acetate, and left the other group untreated. PCRenzyme-linked immunosorbent assay (ELISA), real-time PCR, and galactomannan testing were performed at defined time points during the study.
MATERIALS AND METHODS
In summary, animals were immunosuppressed and inoculated with Aspergillus fumigatus spores. The study had two arms: the arm treated with antifungal therapy (arm A) and the untreated arm (arm B). Each arm consisted of 21 animals, including 3 control animals. Animals were housed in seven groups of three, according to the projected date of euthanasia. Animals in antifungal treatment arm A were treated with 1 mg/kg caspofungin acetate daily for 7 days, beginning 24 h after inoculation. One group of three animals was sacrificed every second day, beginning 2 days postinoculation. One group of three animals in each arm was used as a control group. These animals were dosed with cyclophosphamide but were not treated with antibacterial or antifungal agents and were not inoculated with fungal spores.
Animals. Forty-two adult male Sprague-Dawley rats (mean body weight, 365 g) were used in these experiments. Animals were housed in groups of three in sterile microisolator cages. Animals were allowed ad libitum access to sterile drinking water and a pathogen-free rat diet. All handling and manipulations were performed in a laminar flow cabinet.
Ethical approval for the experiments was obtained from the local animal ethics committee, and animals were monitored and maintained in accordance with local animal ethics guidelines.
Immunosuppression/antibacterial prophylaxis. All animals were immunosuppressed 24 h prior to inoculation, with a single dose of cyclophosphamide (60 mg/kg intraperitoneally). Previous studies have proven that this regimen induces a transient neutropenia (33) (Ͻ0.5 ϫ 10 9 neutrophils/liter) from day 0 to day 4 without undue loss of condition (our unpublished data). Antibacterial prophylaxis commenced 4 days prior to fungal spore inoculation and consisted of ciprofloxacin (1 mg/kg/day) and neomycin (5 mg/kg/day) given by oral gavage. Gentamicin (6 mg/kg subcutaneously) and amoxicillin (50 mg/kg orally) were given daily beginning on the day of inoculation. Animals were inoculated into the lateral tail vein with 0.5 ml of a suspension containing 3 ϫ 10 4 CFU A. fumigatus spores. Previous studies have shown that this inoculum size is sufficient to reliably cause invasive disease that allows survival for at least 10 days (our unpublished data). Control animals were "sham inoculated" with 0.5 ml Tween saline. Animals showing signs of dehydration (weight loss, especially if accompanied by diarrhea and loss of skin elasticity) were given 5 ml sterile saline administered by subcutaneous injection.
Antifungal treatment. Animals in the arm treated with an antifungal agent were treated with caspofungin acetate (1 mg/kg/day) administered by intraperitoneal injection for 7 days beginning 24 h after inoculation.
Microbiology: preparation of fungal spore suspension for inoculation. The strain of A. fumigatus used in these experiments was isolated from the lung biopsy of a patient with cystic fibrosis who developed IA. Testing for sensitivity to caspofungin was performed by E-test (AB Biodisk, Solna, Sweden) to confirm that the isolate was sensitive to caspofungin (0.25 mg/liter).
Fungal spore suspensions were prepared by growing cultures on Sabouraud's dextrose agar for 48 h at 30°C and were then harvested by adding 5 ml Tween saline (0.15 M NaCl containing 0.025% Tween 20) to the plate and rolling over the surface of the colonies. The suspension was counted in a hemocytometer and adjusted to the appropriate concentration in sterile saline solution. Aliquots (100 l) were spread onto triplicate sheep blood agar plates and incubated for 24 h at 30°C, and the number of resulting colonies was counted and averaged, as a confirmation of the manual count.
Animal tissues. Euthanasia was achieved by halothane overdose. Following euthanasia, EDTA and clotted blood samples were collected by cardiac puncture, and organs (liver, lungs, and kidneys) were removed by dissection. Organs were kept at 4°C during transit to the laboratory. EDTA blood samples and sera were frozen and stored at Ϫ20°C until testing.
Once in the laboratory, organs were weighed and examined macroscopically. Macroscopic fungal lesions were graded visually (0, no visible lesions; 1, 1 to 2 lesions; 2, 3 to 10 lesions; 3, 11 to 20 lesions; 4, Ͼ20 lesions). The tissues were then homogenized, 0.1 g of each homogenate was cultured on Sabouraud's dextrose agar at 30°C for 72 h, and the number of resulting colonies were enumerated. Residual fungal tissue burden was expressed as log CFU/gram of tissue.
Molecular methods. PCR-ELISA was performed as described previously (9) . Briefly, pelleted fungal cells were recovered from 1 ml EDTA-anticoagulated blood, followed by enzymatic lysis of fungal cell walls and purification of fungal DNA using a standard phenol-chloroform method. PCR amplification and PCR-ELISA (PCR ELISA DIG-Detection kit; Roche Molecular Biochemicals, Germany) were performed using an oligonucleotide probe that binds specifically to DNA of Aspergillus fumigatus, Aspergillus flavus, and Aspergillus versicolor. Negative controls were included at all steps of the assay to control for environmental or laboratory carryover contamination. The optical density (OD) of each sample was measured on a bench-top spectrophotometer (Elisa II processor; Boehringer GmBH, Germany) at a of 405 nm with a reference of 492 nm. The negative cutoff value was determined as the sum of the negative controls (n ϭ 5) plus 3 standard deviations from the mean. Results were expressed as a positivity index calculated by dividing the OD of the sample by the negative cutoff value. Samples with a positivity index of Ն1.5 were considered positive.
Real-time PCR was performed as described previously (21) . The same aliquot of fungal DNA that was extracted for PCR-ELISA was subjected to real-time PCR using the LightCycler instrument (Roche diagnostics, Mannheim, Germany) and LightCycler software, version 3.5. Reagents were supplied in the LightCycler Hybridization Probes Master Mix kit (Roche diagnostics, Mannheim, Germany). Two internal hybridization probes specific to A. fumigatus were used; the first was labeled at the 5Ј end with LC Red 640 and at the 3Ј end with phosphorous and the second labeled at the 3Ј end with fluorescein as has been previously described (20) .
Galactomannan detection was performed using a commercially available assay kit (Platelia Aspergillus; Sanofi Diagnostics, Marnes-La Coquette, France) according to the manufacturer's instructions. Three hundred microliters of serum was used in each test. Results were expressed as a positivity index calculated by dividing the OD of the sample by the mean of the two threshold sera (supplied by the manufacturer). Samples with a positivity index of Ն1.5 were considered positive, with an equivocal range of Ͻ1.5 to Ն1, (according to the manufacturer's instructions).
Statistical methods. Data were initially entered into a Microsoft Excel spreadsheet. Comparisons within and between groups were made using SPSS version 11 (SPSS Inc. Chicago, Ill.).
RESULTS

Mortality.
One animal in each arm of the study required euthanasia prior to the planned date, on ethical grounds. No samples were obtained from these animals.
Macroscopic fungal disease and culture. Macroscopic lesions were easily identifiable, and the majority of lesions were seen in the livers. The findings are shown in Tables 1 and 2 .
Significantly fewer A. fumigatus colonies were isolated from the liver, spleen, and lung homogenates from caspofungintreated animals than from those of untreated animals (52 ver- (Tables 1 and 2 ). The PCR-ELISA test was a more sensitive test than either the GM assay (P ϭ 0.052) or real-time PCR (P Ͻ 0.01) for the diagnosis of IA. (Tables 1  and 2 ).
The overall values for sensitivity, specificity, positive predictive value, and negative predictive value for each test for diagnosis of IA are shown in Table 3 .
Indices. Median GM indices from animals treated with an antifungal agent showed a trend (P ϭ 0.1) towards higher levels than those of untreated animals, but little effect was observed with PCR-ELISA indices (P ϭ 0.29) (Mann-Whitney U test).
DISCUSSION
We have established a neutropenic rat model of IA using intravenous sublethal inoculation of A. fumigatus spores. This was chosen to ensure a high fungal load but also high survival to the endpoint of the experiment. Tests were done on blood samples taken only at death so that there was sufficient sample to perform all tests in an optimal manner and to avoid com-
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promising animal survival by repeated blood sampling or influencing bloodstream dissemination by repeated handling of the animals. There was obvious macroscopic disease in untreated animals from day 4 and in caspofungin-treated animals from day 6. Despite this, 6 of 25 animals (24%) with obvious macroscopic aspergillosis were negative by all tests. Over the whole population from day 2, the results were more disappointing. The PCR-ELISA test was the most sensitive test for diagnosis of IA in this model (sensitivity, 62%), and by comparison, the other tests performed poorly. There is only one previously published report of the use of real-time PCR testing of blood samples in an animal model (intravenous inoculation) of IA (20) . This study found that only 25% of samples from infected animals were positive. Similarly, in a neutropenic mouse model infected by the tracheal route, 62% of samples were positive by PCR-ELISA (4). These results are all in agreement with the observation from small numbers of human cases of IA that GM and PCR-ELISA may be negative or intermittently positive (12, 16) .
These results are explained in part by the differences in the lower detection limits of the assays. Our own comparisons of these tests in vitro have shown that the PCR-ELISA is 100-fold more sensitive (10 CFU) than either the real-time PCR (100 to 1,000 CFU) or the GM test. Given that the detection limit of the real-time PCR assay used in the present study was at best 10 2 CFU, this suggests that the fungal DNA load seldom reaches this level even with a large burden of disease. This is in keeping with previous estimates of fungal load in blood samples (19) .
The large number of blood samples containing Aspergillus DNA and GM at levels below the detection limit in the face of obvious invasive disease suggests that fungal DNA reaches the bloodstream in an irregular manner, and it is likely that host lysis of hyphae is poor. It is possible that the nature of tissue invasion by A. fumigatus contributes to this phenomenon. It has been shown that platelets and fibrinogen adhere to hyphae of A. fumigatus (7) and participate in fungal killing. Histological sections typically show angioinvasion with regions of associated infarction, indicating that at least partial occlusion of the vessel has occurred. Thus, fungal elements (antigen and DNA) could be contained within this region and hence could be unavailable for detection in the peripheral blood.
Treatment with caspofungin acetate produced a different pattern of results from the untreated group. There were strikingly fewer colonies of A. fumigatus from organ homogenate (29 versus 98), but the sensitivity of the PCR-ELISA assay was similar for the untreated group, and there was a high rate of detection of galactomannan, in terms of both the number of animals returning positive results and the mean or median GM positivity index of treated animals. The paradoxical relationship between caspofungin administration and clinical improvement but stable or increasing GM indices was previously reported by Petraitiene et al., who described the same effect in an experimental rabbit model of IA (26) . These observations are also in keeping with reports of clinical improvement following echinocandin therapy but stable or increasing tissue burden and circulating GM compared to untreated controls. Echinocandins inhibit apical-tip growth and may promote fragmentation that releases more GM and possibly DNA into the circulation (15) . This pattern differs from that of azoles (with the exception of itraconazole) and deoxycholate amphotericin B at therapeutic dosages, all of which significantly decrease tissue Aspergillus burden, improve survival and decrease morbidity, and decrease or eliminate GM from the serum (5, 11, 23-25, 27, 30) . These studies clearly demonstrate that the relationship between tissue burden and fungal GM or DNA levels in the circulating blood is complex, especially when an antifungal agent is being used. In our study, there was no correlation between tissue burden and GM or PCR-ELISA positivity. The nature of antifungal treatment needs to be taken into account when considering the value of both GM and PCR-ELISA as diagnostic tests or when monitoring the response to therapy as well as other factors that predispose to variable sensitivity or false-positive results (1, 2, 31, 37-39). Few studies have been designed to specifically study the effect of the administration of antifungal agents on the performance of the test. The results of this and other studies suggest that the use of GM levels in serum to guide treatment in neutropenic hosts should be treated with caution, especially if the patient is receiving antifungal therapy with an echinocandin. In summary, the results of this study show that GM assay and PCR-ELISA used for the diagnosis of IA may return negative results even in cases of invasive disease. While much has been made of the various causes of false-positive results for these tests, the nature of the invasive process of A. fumigatus may cause false-negative results, and the use of antifungal therapy may influence the performance of these tests. The value of these tests needs to be better defined and investigated.
